eXmoor Pharma Concepts Ltd

eXmoor and Virica receive funding to improve AAV gene therapy manufacturing. Partners will develop formulations of VSEs™ and validate their ability to improve yields of adeno-associated vector (AAVs) at scale, lowering gene therapy costs at commercial scale. Virica and eXmoor will receive advisory services and funding through collaborative Canada-UK government program.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

eXmoor’s Cell & Gene Therapy Centre can now offer a full range of GMP services for cell and gene therapies including manufacture, fill/finish, packaging, labelling, and shipping to global clinical sites